OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer
Sandro Pignata, Michael A. Bookman, Jalid Sehouli, et al.
Gynecologic Oncology (2023) Vol. 177, pp. 20-31
Closed Access | Times Cited: 10
Sandro Pignata, Michael A. Bookman, Jalid Sehouli, et al.
Gynecologic Oncology (2023) Vol. 177, pp. 20-31
Closed Access | Times Cited: 10
Showing 10 citing articles:
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García, et al.
The Lancet (2023) Vol. 403, Iss. 10421, pp. 31-43
Open Access | Times Cited: 101
Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García, et al.
The Lancet (2023) Vol. 403, Iss. 10421, pp. 31-43
Open Access | Times Cited: 101
Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors
Elena Catanzaro, Manuel Beltrán‐Visiedo, Lorenzo Galluzzi, et al.
Cellular and Molecular Immunology (2024)
Open Access | Times Cited: 11
Elena Catanzaro, Manuel Beltrán‐Visiedo, Lorenzo Galluzzi, et al.
Cellular and Molecular Immunology (2024)
Open Access | Times Cited: 11
Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial
Antonio González‐Martín, María Jesús Rubio, Florian Heitz, et al.
Journal of Clinical Oncology (2024)
Closed Access | Times Cited: 4
Antonio González‐Martín, María Jesús Rubio, Florian Heitz, et al.
Journal of Clinical Oncology (2024)
Closed Access | Times Cited: 4
Advanced Therapeutic Approaches for Metastatic Ovarian Cancer
Soohyun Choe, Mir Jeon, Hyunho Yoon
Cancers (2025) Vol. 17, Iss. 5, pp. 788-788
Open Access
Soohyun Choe, Mir Jeon, Hyunho Yoon
Cancers (2025) Vol. 17, Iss. 5, pp. 788-788
Open Access
Combination therapy with Chicoric acid and PD-1/PD-L1 blockade improves the immunotherapy response in patient-derived ovarian cancer xenograft model
Hongwei Lan, Jingjuan Zhu, Helei Hou, et al.
Cell Communication and Signaling (2025) Vol. 23, Iss. 1
Open Access
Hongwei Lan, Jingjuan Zhu, Helei Hou, et al.
Cell Communication and Signaling (2025) Vol. 23, Iss. 1
Open Access
Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial
Benoît You, Charles Anderson, Sabrina Chiara Cecere, et al.
Gynecologic Oncology (2025) Vol. 197, pp. 66-73
Open Access
Benoît You, Charles Anderson, Sabrina Chiara Cecere, et al.
Gynecologic Oncology (2025) Vol. 197, pp. 66-73
Open Access
Bevacizumab in ovarian cancer therapy: current advances, clinical challenges, and emerging strategies
Mingyue Zhang, Jun Zhu, Yin Bao, et al.
Frontiers in Bioengineering and Biotechnology (2025) Vol. 13
Open Access
Mingyue Zhang, Jun Zhu, Yin Bao, et al.
Frontiers in Bioengineering and Biotechnology (2025) Vol. 13
Open Access
Examining the Evidence for Immune Checkpoint Therapy in High-Grade Serous Ovarian Cancer
Adele E. Connor, PATRICK LYONS, Aoife Kilgallon, et al.
Heliyon (2024) Vol. 10, Iss. 20, pp. e38888-e38888
Open Access | Times Cited: 3
Adele E. Connor, PATRICK LYONS, Aoife Kilgallon, et al.
Heliyon (2024) Vol. 10, Iss. 20, pp. e38888-e38888
Open Access | Times Cited: 3
Navigating immunotherapy for ovarian cancer: current landscape and future perspectives
Maurizio Capuozzo, Francesco Ferrara, Claudia Cinque, et al.
Journal of Cancer Metastasis and Treatment (2024)
Open Access | Times Cited: 1
Maurizio Capuozzo, Francesco Ferrara, Claudia Cinque, et al.
Journal of Cancer Metastasis and Treatment (2024)
Open Access | Times Cited: 1
Effect of neoadjuvant chemotherapy on the immune microenvironment of gynaecological tumours
Jing Xue, Yan Xia, Qin Ding, et al.
Annals of Medicine (2023) Vol. 55, Iss. 2
Open Access | Times Cited: 3
Jing Xue, Yan Xia, Qin Ding, et al.
Annals of Medicine (2023) Vol. 55, Iss. 2
Open Access | Times Cited: 3
Advancing Ovarian Cancer Treatment: The Latest Insights on PARP Inhibitors from ASCO 2023
Yves van Roon, Marcus Vetter
healthbook TIMES Oncology Hematology (2023), Iss. 18
Open Access
Yves van Roon, Marcus Vetter
healthbook TIMES Oncology Hematology (2023), Iss. 18
Open Access
